Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology case study is a Harvard Business School (HBR) case study written by Julian Birkinshaw, Ivanka Visnjic, Simon Best. The Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology (referred as “Biotechnology Movers” from here on) case study provides evaluation & decision scenario in field of Strategy & Execution. It also touches upon business topics such as - Value proposition, Disruptive innovation, Mergers & acquisitions.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology Case Study

How do incumbent firms respond over time to a potentially disruptive technology? This article documents the strategies of 12 large pharmaceutical firms over 25 years as they addressed the opportunity/threat of biotechnology. All showed awareness of biotechnology's potential, but their response profiles varied dramatically in terms of timing (early/late) and focus (external/internal). Late movers mostly made large acquisitions to "catch up," but early movers maintained their lead in terms of biotechnology-based drug sales and profitability, and those with a more "open" response profile performed better. This response involves a three-step process: building awareness (sensing), building capability (responding), and building commitment (scaling).

Case Authors : Julian Birkinshaw, Ivanka Visnjic, Simon Best

Topic : Strategy & Execution

Related Areas : Disruptive innovation, Mergers & acquisitions

---

Calculating Net Present Value (NPV) at 6% for Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10026036)	-10026036	-	-
Year 1	3454615	-6571421	3454615	0.9434	3259071
Year 2	3979831	-2591590	7434446	0.89	3542035
Year 3	3957801	1366211	11392247	0.8396	3323046
Year 4	3227295	4593506	14619542	0.7921	2556320
TOTAL			14619542		12680472

The Net Present Value at 6% discount rate is 2654436

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Net Present Value
2. Payback Period
3. Profitability Index
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Biotechnology Movers shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Biotechnology Movers have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.

---

Formula and Steps to Calculate Net Present Value (NPV) of Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Strategy & Execution Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Biotechnology Movers often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Biotechnology Movers needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10026036)	-10026036	-	-
Year 1	3454615	-6571421	3454615	0.8696	3004013
Year 2	3979831	-2591590	7434446	0.7561	3009324
Year 3	3957801	1366211	11392247	0.6575	2602318
Year 4	3227295	4593506	14619542	0.5718	1845216
TOTAL					10460872

The Net NPV after 4 years is 434836

(10460872 - 10026036 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10026036)	-10026036	-	-
Year 1	3454615	-6571421	3454615	0.8333	2878846
Year 2	3979831	-2591590	7434446	0.6944	2763772
Year 3	3957801	1366211	11392247	0.5787	2290394
Year 4	3227295	4593506	14619542	0.4823	1556373
TOTAL					9489384

The Net NPV after 4 years is -536652

At 20% discount rate the NPV is negative (9489384 - 10026036 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Biotechnology Movers to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Biotechnology Movers has a NPV value higher than Zero then finance managers at Biotechnology Movers can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Biotechnology Movers, then the stock price of the Biotechnology Movers should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Biotechnology Movers should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Understanding of risks involved in the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology

References & Further Readings

Julian Birkinshaw, Ivanka Visnjic, Simon Best (2018), "Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology Harvard Business Review Case Study. Published by HBR Publications.